Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Cotinine is the major metabolite of nicotine and has displayed some capacity for improving cognition in mouse models following chronic administration. We tested if acute cotinine treatment is capable of improving cognition in the mouse model of Fragile X syndrome, Fmr1−/− knockout mice, and if this is related to inhibition by cotinine treatment of glycogen synthase kinase-3β (GSK3β), which is abnormally active in Fmr1−/− mice. Acute cotinine treatment increased the inhibitory serine-phosphorylation of GSK3β and the activating phosphorylation of AKT, which can mediate serine-phosphorylation of GSK3β, in both wild-type and Fmr1−/− mouse hippocampus. Acute cotinine treatment improved cognitive functions of Fmr1−/− mice in coordinate and categorical spatial processing, novel object recognition, and temporal ordering. However, cotinine failed to restore impaired cognition in GSK3β knockin mice, in which a serine9-to-alanine9 mutation blocks the inhibitory serine phosphorylation of GSK3β, causing GSK3β to be hyperactive. These results indicate that acute cotinine treatment effectively repairs impairments of these four cognitive tasks in Fmr1−/− mice, and suggest that this cognition-enhancing effect of cotinine is linked to its induction of inhibitory serine-phosphorylation of GSK3. Taken together, these results show that nicotinic receptor agonists can act as cognitive enhancers in a mouse model of Fragile X syndrome and highlight the potential role of inhibiting GSK3β in mediating the beneficial effects of cotinine on memory.

Original languageEnglish (US)
Pages (from-to)490-498
Number of pages9
JournalEuropean Journal of Neuroscience
Volume45
Issue number4
DOIs
StatePublished - Feb 1 2017

Fingerprint

Fragile X Syndrome
Cotinine
Glycogen Synthase Kinase 3
Cognition
Serine
Phosphorylation
Nicotinic Agonists
Nootropic Agents
Nicotinic Receptors
Nicotine
Knockout Mice
Hippocampus
Mutation

Keywords

  • cotinine
  • Fragile X syndrome
  • glycogen synthase kinase-3
  • novel object recognition
  • spatial memory

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome. / Pardo, Marta; Beurel, Eleonore; Jope, Richard S.

In: European Journal of Neuroscience, Vol. 45, No. 4, 01.02.2017, p. 490-498.

Research output: Contribution to journalArticle

@article{9a0347de8da546af982fe7ea3e419345,
title = "Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome",
abstract = "Cotinine is the major metabolite of nicotine and has displayed some capacity for improving cognition in mouse models following chronic administration. We tested if acute cotinine treatment is capable of improving cognition in the mouse model of Fragile X syndrome, Fmr1−/− knockout mice, and if this is related to inhibition by cotinine treatment of glycogen synthase kinase-3β (GSK3β), which is abnormally active in Fmr1−/− mice. Acute cotinine treatment increased the inhibitory serine-phosphorylation of GSK3β and the activating phosphorylation of AKT, which can mediate serine-phosphorylation of GSK3β, in both wild-type and Fmr1−/− mouse hippocampus. Acute cotinine treatment improved cognitive functions of Fmr1−/− mice in coordinate and categorical spatial processing, novel object recognition, and temporal ordering. However, cotinine failed to restore impaired cognition in GSK3β knockin mice, in which a serine9-to-alanine9 mutation blocks the inhibitory serine phosphorylation of GSK3β, causing GSK3β to be hyperactive. These results indicate that acute cotinine treatment effectively repairs impairments of these four cognitive tasks in Fmr1−/− mice, and suggest that this cognition-enhancing effect of cotinine is linked to its induction of inhibitory serine-phosphorylation of GSK3. Taken together, these results show that nicotinic receptor agonists can act as cognitive enhancers in a mouse model of Fragile X syndrome and highlight the potential role of inhibiting GSK3β in mediating the beneficial effects of cotinine on memory.",
keywords = "cotinine, Fragile X syndrome, glycogen synthase kinase-3, novel object recognition, spatial memory",
author = "Marta Pardo and Eleonore Beurel and Jope, {Richard S}",
year = "2017",
month = "2",
day = "1",
doi = "10.1111/ejn.13446",
language = "English (US)",
volume = "45",
pages = "490--498",
journal = "European Journal of Neuroscience",
issn = "0953-816X",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Cotinine administration improves impaired cognition in the mouse model of Fragile X syndrome

AU - Pardo, Marta

AU - Beurel, Eleonore

AU - Jope, Richard S

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Cotinine is the major metabolite of nicotine and has displayed some capacity for improving cognition in mouse models following chronic administration. We tested if acute cotinine treatment is capable of improving cognition in the mouse model of Fragile X syndrome, Fmr1−/− knockout mice, and if this is related to inhibition by cotinine treatment of glycogen synthase kinase-3β (GSK3β), which is abnormally active in Fmr1−/− mice. Acute cotinine treatment increased the inhibitory serine-phosphorylation of GSK3β and the activating phosphorylation of AKT, which can mediate serine-phosphorylation of GSK3β, in both wild-type and Fmr1−/− mouse hippocampus. Acute cotinine treatment improved cognitive functions of Fmr1−/− mice in coordinate and categorical spatial processing, novel object recognition, and temporal ordering. However, cotinine failed to restore impaired cognition in GSK3β knockin mice, in which a serine9-to-alanine9 mutation blocks the inhibitory serine phosphorylation of GSK3β, causing GSK3β to be hyperactive. These results indicate that acute cotinine treatment effectively repairs impairments of these four cognitive tasks in Fmr1−/− mice, and suggest that this cognition-enhancing effect of cotinine is linked to its induction of inhibitory serine-phosphorylation of GSK3. Taken together, these results show that nicotinic receptor agonists can act as cognitive enhancers in a mouse model of Fragile X syndrome and highlight the potential role of inhibiting GSK3β in mediating the beneficial effects of cotinine on memory.

AB - Cotinine is the major metabolite of nicotine and has displayed some capacity for improving cognition in mouse models following chronic administration. We tested if acute cotinine treatment is capable of improving cognition in the mouse model of Fragile X syndrome, Fmr1−/− knockout mice, and if this is related to inhibition by cotinine treatment of glycogen synthase kinase-3β (GSK3β), which is abnormally active in Fmr1−/− mice. Acute cotinine treatment increased the inhibitory serine-phosphorylation of GSK3β and the activating phosphorylation of AKT, which can mediate serine-phosphorylation of GSK3β, in both wild-type and Fmr1−/− mouse hippocampus. Acute cotinine treatment improved cognitive functions of Fmr1−/− mice in coordinate and categorical spatial processing, novel object recognition, and temporal ordering. However, cotinine failed to restore impaired cognition in GSK3β knockin mice, in which a serine9-to-alanine9 mutation blocks the inhibitory serine phosphorylation of GSK3β, causing GSK3β to be hyperactive. These results indicate that acute cotinine treatment effectively repairs impairments of these four cognitive tasks in Fmr1−/− mice, and suggest that this cognition-enhancing effect of cotinine is linked to its induction of inhibitory serine-phosphorylation of GSK3. Taken together, these results show that nicotinic receptor agonists can act as cognitive enhancers in a mouse model of Fragile X syndrome and highlight the potential role of inhibiting GSK3β in mediating the beneficial effects of cotinine on memory.

KW - cotinine

KW - Fragile X syndrome

KW - glycogen synthase kinase-3

KW - novel object recognition

KW - spatial memory

UR - http://www.scopus.com/inward/record.url?scp=85001781155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85001781155&partnerID=8YFLogxK

U2 - 10.1111/ejn.13446

DO - 10.1111/ejn.13446

M3 - Article

C2 - 27775852

AN - SCOPUS:85001781155

VL - 45

SP - 490

EP - 498

JO - European Journal of Neuroscience

JF - European Journal of Neuroscience

SN - 0953-816X

IS - 4

ER -